prednisone has been researched along with Chemotherapy-Induced Febrile Neutropenia in 13 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
Chemotherapy-Induced Febrile Neutropenia: FEVER accompanied by a significant reduction in NEUTROPHIL count associated with CHEMOTHERAPY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Despite improvements in standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with untreated, diffuse large B-cell lymphoma, up to 40% of these patients relapse." | 9.17 | Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. ( Baldi, I; Bottelli, C; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; De Masi, P; Gaidano, G; Ladetto, M; Liberati, AM; Orsucci, L; Palumbo, A; Pavone, V; Perticone, S; Rossi, G; Rossini, B; Salvi, F; Tucci, A; Vitolo, U; Zanni, M, 2013) |
| "Despite improvements in standard therapy with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for patients with untreated, diffuse large B-cell lymphoma, up to 40% of these patients relapse." | 5.17 | Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. ( Baldi, I; Bottelli, C; Carella, AM; Castellino, A; Chiappella, A; Ciccone, G; De Masi, P; Gaidano, G; Ladetto, M; Liberati, AM; Orsucci, L; Palumbo, A; Pavone, V; Perticone, S; Rossi, G; Rossini, B; Salvi, F; Tucci, A; Vitolo, U; Zanni, M, 2013) |
| "Febrile neutropenia (FN) is the major toxicity of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) regimen in the treatment of diffuse large B-cell lymphoma (DLBCL)." | 3.80 | Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP. ( Ahn, MS; Choi, JH; Choi, YW; Jeong, SH; Jin, UR; Kang, SY; Lee, HW; Park, JS, 2014) |
| "005) and mean daily prednisone dosage (29." | 1.40 | Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide. ( Adams, A; Alperin, R; Barinstein, L; Lehman, TJ; Moorthy, N; Ramanathan, A; Singh, C, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Ise, M | 1 |
| Matsuda, K | 1 |
| Shimura, A | 1 |
| Masamoto, Y | 1 |
| Kurokawa, M | 1 |
| Jeon, SY | 1 |
| Yhim, HY | 1 |
| Kim, HS | 1 |
| Kim, JA | 1 |
| Yang, DH | 1 |
| Kwak, JY | 1 |
| Garcia-Sanz, R | 1 |
| Sureda, A | 1 |
| de la Cruz, F | 1 |
| Canales, M | 1 |
| Gonzalez, AP | 1 |
| Pinana, JL | 1 |
| Rodriguez, A | 1 |
| Gutierrez, A | 1 |
| Domingo-Domenech, E | 1 |
| Sanchez-Gonzalez, B | 1 |
| Rodriguez, G | 1 |
| Lopez, J | 1 |
| Moreno, M | 1 |
| Rodriguez-Salazar, MJ | 1 |
| Jimenez-Cabrera, S | 1 |
| Caballero, MD | 1 |
| Martinez, C | 1 |
| Cheung, CY | 1 |
| Chak, WL | 1 |
| Yokoyama, M | 1 |
| Kusano, Y | 1 |
| Nishihara, A | 1 |
| Inoue, N | 1 |
| Nishimura, N | 1 |
| Mishima, Y | 1 |
| Terui, Y | 1 |
| Nukada, T | 1 |
| Nomura, T | 1 |
| Hatake, K | 1 |
| Chiappella, A | 1 |
| Tucci, A | 1 |
| Castellino, A | 1 |
| Pavone, V | 1 |
| Baldi, I | 1 |
| Carella, AM | 1 |
| Orsucci, L | 1 |
| Zanni, M | 1 |
| Salvi, F | 1 |
| Liberati, AM | 1 |
| Gaidano, G | 1 |
| Bottelli, C | 1 |
| Rossini, B | 1 |
| Perticone, S | 1 |
| De Masi, P | 1 |
| Ladetto, M | 1 |
| Ciccone, G | 1 |
| Palumbo, A | 1 |
| Rossi, G | 1 |
| Vitolo, U | 1 |
| Lehman, TJ | 1 |
| Singh, C | 1 |
| Ramanathan, A | 1 |
| Alperin, R | 1 |
| Adams, A | 1 |
| Barinstein, L | 1 |
| Moorthy, N | 1 |
| Langeberg, WJ | 1 |
| Siozon, CC | 1 |
| Page, JH | 1 |
| Morrow, PK | 1 |
| Chia, VM | 1 |
| Shiota, M | 1 |
| Yokomizo, A | 1 |
| Takeuchi, A | 1 |
| Kiyoshima, K | 1 |
| Inokuchi, J | 1 |
| Tatsugami, K | 1 |
| Naito, S | 1 |
| Kikuchi, M | 1 |
| Nakasone, H | 1 |
| Akahoshi, Y | 1 |
| Nakano, H | 1 |
| Ugai, T | 1 |
| Wada, H | 1 |
| Yamasaki, R | 1 |
| Sakamoto, K | 1 |
| Kawamura, K | 1 |
| Ishihara, Y | 1 |
| Sato, M | 1 |
| Ashizawa, M | 1 |
| Terasako-Saito, K | 1 |
| Kimura, S | 1 |
| Yamazaki, R | 1 |
| Kako, S | 1 |
| Kanda, J | 1 |
| Nishida, J | 1 |
| Sekiguchi, N | 1 |
| Noto, S | 1 |
| Kida, M | 1 |
| Hangaishi, A | 1 |
| Usuki, K | 1 |
| Kanda, Y | 1 |
| Balducci, L | 1 |
| Mo, M | 1 |
| Abella, E | 1 |
| Saven, A | 1 |
| Choi, YW | 1 |
| Jeong, SH | 1 |
| Ahn, MS | 1 |
| Lee, HW | 1 |
| Kang, SY | 1 |
| Choi, JH | 1 |
| Jin, UR | 1 |
| Park, JS | 1 |
| Smith, TJ | 1 |
| Hillner, BE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of Treatment With Lenalidomide Plus R-CHOP21 (LR-CHOP21) for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (DLBCL)[NCT00907348] | Phase 2 | 49 participants (Anticipated) | Interventional | 2007-10-31 | Active, not recruiting | ||
| National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation[NCT02340936] | Phase 1/Phase 2 | 53 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for prednisone and Chemotherapy-Induced Febrile Neutropenia
11 other studies available for prednisone and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Primary prophylaxis with pegfilgrastim during the first cycle of R-CHOP to avoid reduction of dose intensity in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febril | 2021 |
The effect of the dexamethasone, cytarabine, and cisplatin (DHAP) regimen on stem cell mobilization and transplant outcomes of patients with non-Hodgkin's lymphoma who are candidates for up-front autologous stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy | 2018 |
A rare diagnosis of primary native kidney non-hodgkin's lymphoma after kidney transplantation.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bone N | 2019 |
Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy-Induced Febrile Neutropenia; Cyclophosp | 2020 |
Prolonged improvement of childhood onset systemic lupus erythematosus following systematic administration of rituximab and cyclophosphamide.
Topics: Adolescent; Adult; Age of Onset; Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Chemo | 2014 |
Use of pegfilgrastim primary prophylaxis and risk of infection, by chemotherapy cycle and regimen, among patients with breast cancer or non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2014 |
Risk factors for febrile neutropenia in patients receiving docetaxel chemotherapy for castration-resistant prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutrop | 2014 |
Reduced-dose (two-thirds) R-CHOP chemotherapy for elderly patients with non-Hodgkin lymphoma.
Topics: Academic Medical Centers; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Murine-Derived; An | 2015 |
Retrospective analysis of relative dose intensity in patients with non-Hodgkin lymphoma receiving CHOP-based chemotherapy and pegfilgrastim.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic A | 2014 |
Patterns of neutropenia and risk factors for febrile neutropenia of diffuse large B-cell lymphoma patients treated with rituximab-CHOP.
Topics: Adolescent; Adult; Age Factors; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combine | 2014 |
Real-World Conundrums and Biases in the Use of White Cell Growth Factors.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biosimilar P | 2016 |